QURE - uniQure N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
31 20 240 6000

Full-time employees501

Key executives

NameTitlePayExercisedYear born
Mr. Matthew Craig KapustaCEO & Exec. Director1.16MN/A1972
Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site566.36kN/A1973
Mr. Pierre CalozChief Operating Officer951.1kN/A1972
Dr. Ricardo Dolmetsch Ph.D.Pres of R&D911.07kN/A1969
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance OfficerN/AN/A1962
Dr. Tamara Tugal Ph.D., MBABus. Devel. DirectorN/AN/AN/A
Ms. Erin BoyerChief People & Culture OfficeN/AN/AN/A
Ms. Maria E. CantorChief Corp. Affairs OfficerN/AN/A1968
Mr. Richard Porter Ph.D.Chief Bus. OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate governance

uniQure N.V.’s ISS governance QualityScore as of 1 June 2023 is 3. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.